Neurocrine Biosciences Announces The FDA Has Granted Fast Track Designation For VMAT2 Inhibitor NBI-98854

Neurocrine Biosciences, Inc. NBIX announced today that its VMAT2 inhibitor product candidate, NBI-98854, has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of neuroleptic-induced tardive dyskinesia. The FDA's Fast Track program is designed to facilitate the development and expedite the review of drugs intended to treat serious diseases and address unmet medical needs. The Fast Track designation allows more frequent interactions with the FDA during the drug development process, which assures that questions and issues are resolved quickly, often leading to earlier drug approval and access by patients.